We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Rapid HIV Tests Performed on Minute Blood Samples

By HospiMedica staff writers
Posted on 01 May 2006
New HIV tests detect HIV-1 and HIV-2 antibodies in four different matrices: finger-stick whole blood, venous whole blood, serum, and plasma. More...
Tests are complete within approximately 15 minutes of sample application.

Chembio Diagnostics, Inc. (Medford, NY, USA) has received an "approvable” letter from the U.S. Food and Drug Administration (FDA, Rockville, MD, USA) for its Sure Check HIV 1/2 and HIV 1/2 Stat-Pak rapid test Pre-Market Applications (PMA). Chembio's PMA approval is subject only to final review by the FDA of the products' package inserts and other standard conditions related to all PMAs. Chembio anticipates that the approval will be given very soon allowing the company to market its tests to clinical laboratories and hospitals in the United States.

Easy to perform, the two new rapid tests are highly sensitive and specific. They are safe, requiring as little as 2.5-5.0 µl, which is easily obtained from a finger prick. However, the FDA PMA approval, when granted, will be also for whole blood, serum, and plasma samples. Both products have a built-in internal control (a true IgG), and provide a 24-month shelf life at 8-30º C.

"Estimates are that as much as one-third of those infected with HIV in the US population are not aware of their HIV-Positive status. We believe that that these individuals are much more likely to access testing services if test results and counseling can be delivered at point of care,” said Lawrence Siebert, president and CEO of Chembio. Mr. Siebert continued, "The U.S. is a very important market for Chembio and those that need to be tested, as there are only two competitive products currently approved. Moreover, we believe that PMA approval, when granted, will provide further impetus to our international marketing efforts, including opening markets not currently available.”

Chembio is one of the four recommended global rapid HIV test suppliers under the U.S. Clinton HIV/AIDS initiative. The company has also developed tests for other diseases including human and veterinary tuberculosis, and Chagas disease.



Related Links:
Chembio Diagnostics
Clinton HIV/AIDS initiative

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Pulmonary Ventilator
OXYMAG
PACS Workstation
PaxeraView PRO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.